English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Jump to
    • With Sun Pharma-Merck striking JV, why is SPARC shining?

      With Sun Pharma-Merck striking JV, why is SPARC shining?

      According to CNBC-TV18's research analyst Ekta Batra it's SPARC which has emerged as the winner from this deal between Sun Pharma and Merck. They are targeting a portfolio of around 12 drugs in around 100 countries but the focus is expected to be the top 10 countries which are expected to contribute around 80% of revenues.

    • What is Lupin's acquisition agenda for the future?

      What is Lupin's acquisition agenda for the future?

      Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347